{{Rsnum
|rsid=4251545
|Gene=IRAK4
|Chromosome=12
|position=43786492
|Orientation=plus
|GMAF=0.1501
|Gene_s=IRAK4
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.9 | 14.2 | 85.0
| HCB | 0.0 | 14.7 | 85.3
| JPT | 0.0 | 11.5 | 88.5
| YRI | 8.2 | 42.2 | 49.7
| ASW | 15.8 | 40.4 | 43.9
| CHB | 0.0 | 14.7 | 85.3
| CHD | 1.9 | 20.8 | 77.4
| GIH | 1.0 | 16.8 | 82.2
| LWK | 10.9 | 43.6 | 45.5
| MEX | 1.7 | 19.0 | 79.3
| MKK | 8.4 | 45.8 | 45.8
| TSI | 0.0 | 21.6 | 78.4
| HapMapRevision=28
}}{{PMID Auto
|PMID=23657238
|Title=Toll-like receptor-associated sequence variants and prostate cancer risk among men of African descent
|OA=1
}}

{{PMID Auto
|PMID=24194738
|Title=IRAK4 and TLR3 Sequence Variants may Alter Breast Cancer Risk among African-American Women
|OA=1
}}

{{PMID Auto
|PMID=19505919
|Title=Toll-like receptor signaling pathway variants and prostate cancer mortality.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}